KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) FCF Margin: 2009-2025

Historic FCF Margin for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to 37.75%.

  • Regeneron Pharmaceuticals' FCF Margin rose 955.00% to 37.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.63%, marking a year-over-year increase of 479.00%. This contributed to the annual value of 25.80% for FY2024, which is 374.00% down from last year.
  • According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' FCF Margin is 37.75%, which was up 49.94% from 25.18% recorded in Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' FCF Margin peaked at 3,919.80% during Q1 2022, and registered a low of 4.89% during Q2 2024.
  • Its 3-year average for FCF Margin is 28.51%, with a median of 28.06% in 2024.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' FCF Margin skyrocketed by 389,792bps in 2022 and then slumped by 388,219bps in 2023.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' FCF Margin stood at 44.78% in 2021, then spiked by 152,292bps to 1,567.70% in 2022, then crashed by 154,329bps to 24.41% in 2023, then skyrocketed by 365bps to 28.06% in 2024, then surged by 955bps to 37.75% in 2025.
  • Its FCF Margin was 37.75% in Q3 2025, compared to 25.18% in Q2 2025 and 26.94% in Q1 2025.